The European Commission has published its contract with drug-maker AstraZeneca to buy the company's Covid vaccine, amid a row over supplies.
The move, agreed with AstraZeneca, came hours after Commission chief Ursula von der Leyen increased pressure on the firm over its decision to cut supplies.
The contract signed in August contained "binding orders", she told German radio, and called for an explanation.
The vaccine was approved by the EU medicines regulator on Friday.
The EU wanted to publish the contract to bolster its argument that the company had reneged on its commitments.
The company's chief executive, Pascal Soriot, said in an interview earlier this week that the contract obliged AstraZeneca to make its "best effort" to meet EU demand, without compelling the company to stick to a specific timetable.
Large sections of the contract have been blanked out - redacted - to protect sensitive information.
These include some paragraphs dealing with costs, guaranteed delivery dates and intellectual property.
What is the issue?
The August deal was for 300 million doses for the EU, to be delivered after regulatory approval, with an option for 100 million more.
But EU sources say they now expect to get only about a quarter of the 100 million vaccines they were expecting to receive by March, a shortfall of about 75 million jabs.
The EU is under pressure after criticism that the pace of vaccinations in several member states has been too slow.
AstraZeneca says the production problems are at its plants in the Netherlands and Belgium.
Supplies of another vaccine, produced by Pfizer-BioNTech, have also dropped due to production issues.
What is the EU saying?
EU officials say AstraZeneca has been asked to send some doses manufactured in the UK to the continent to make up the shortfall, but the company said on Wednesday that its contract for UK supplies prevented this.
An EU source familiar with the talks told the BBC that AstraZeneca's UK facilities were obliged to supply vaccine to the EU.
"This is not an option, it is a contractual obligation… a declaration by AstraZeneca as to where the drug substance manufacturing will take place." The UK plants are not back-up facilities; they are part of the main network, the source added.
"There are binding orders and the contract is crystal clear," Mrs von der Leyen said in Friday morning's radio interview.
"'Best effort' was valid while it was still unclear whether they could develop a vaccine. That time is behind us. The vaccine is there.
"AstraZeneca has also explicitly assured us in this contract that no other obligations would prevent the contract from being fulfilled," she said.
The BBC's Europe correspondent, Gavin Lee, says it may come down to specialist legal interpretation, and some fine tooth-combing, to understand who's right.
